key: cord-0690667-ewnxbjyj
authors: Krzywicka, Katarzyna; van de Munckhof, Anita; Zimmermann, Julian; Bode, Felix J.; Frisullo, Giovanni; Karapanayiotides, Theodoros; Pötzsch, Bernd; Sánchez van Kammen, Mayte; Heldner, Mirjam R.; Arnold, Marcel; Kremer Hovinga, Johanna A.; Ferro, José M.; Aguiar de Sousa, Diana; Coutinho, Jonathan M.
title: Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose
date: 2022-04-28
journal: Blood
DOI: 10.1182/blood.2021015329
sha: 5166d37de78659437e27672c6e26a17e0759cac4
doc_id: 690667
cord_uid: ewnxbjyj

nan

So far, no definite VITT cases occurring after a second ChAdOx1 nCoV-19 vaccine dose have been reported, raising the question of whether VITT only occurs after a first dose. Two pharmacovigilance studies reported cases of thrombosis with thrombocytopenia after a second ChAdOx1 nCoV-19 dose, but because of lack of clinical data, none of these could be classified as VITT. [7] [8] [9] Knowledge on whether VITT can occur after a second ChAdOx1 nCoV-19 dose is relevant for clinicians and policymakers, especially in low-and middleincome countries, which are currently the main users of adenovirus-based vaccines. 10 We used data from the "CVT after SARS-CoV-2 vaccination" registry 4,11 to identify VITT-related CVT cases occurring after a second ChAdOx1 nCoV-19 dose.

Details of this registry have been published. 4 Briefly, this ongoing study collects data on patients with CVT with symptom onset #28 days from SARS-CoV-2 vaccination, regardless of the type and dose of vaccine. The study is endorsed by the European Academy of Neurology and the European Stroke Organization. Investigators are instructed to report consecutive cases from their hospitals. The ethical review board of the Academic Medical Centre issued a waiver of formal approval for this observational study. Each center obtained local permission to carry out the study and acquired informed consent for the use of pseudonymized care data according to national law.

We used the case definition criteria of the United Kingdom expert hematology panel to classify cases as definite, probable, possible, or unlikely VITT after ChAdOx1 nCoV-19 administration among CVT cases reported until 1 December 2021. 9 Within the study period, 202 CVT cases after SARS-CoV-2 vaccination were reported from 24 countries ( Figure 1 ). Of the 124 patients with CVT following ChAdOx1 nCoV-19 vaccination, 120 were after a first dose, and 4 were after a second dose. There were 61 definite, 20 probable, 10 possible, and 29 unlikely VITT cases after a first ChAdOx1 nCoV-19 dose. Of the 4 cases after the second dose, 1 was definite, 1 was probable, 1 was possible, and 1 was an unlikely VITT. There were no possible, probable, or definite VITT cases after the second dose of any of the other vaccines.

Details of the 4 cases after a second ChAdOx1 nCoV-19 dose are provided in Table 1 *According to the United Kingdom expert hematology panel. 9 †To avoid the possibility of patient identification, exact age has been removed. ‡In all cases, the first vaccination was ChAdOx1 nCoV-19. §Blood was drawn from the patient at admission, stored at 4 C for 1 wk, then stored at 220 C for 327 d before it was tested.

jjModified HIPA assay was performed as previously described. 15 ¶HIMEA assay was performed as previously described. 16 #Reason: multiple intracerebral hemorrhages and diffuse subarachnoid hemorrhage.

**Worsening of intracerebral hemorrhages.

the cases is provided in supplemental Figures 1-4 , available on the Blood Web site. None of the patients reported any symptoms after the first dose of ChAdOx1 nCoV-19. The patients (3 men, 1 woman) were between their forties and sixties. None had preexistent comorbidities. The interval between receiving the second vaccine dose and symptom onset varied between 1 and 6 days. The 2 patients who met the criteria for probable and definite VITT (patients 1 and 2) both died of brain herniation.

In patient 3 with symptom onset on day 1, the rapid onset could be explained if circulating anti-PF4 antibodies were present after the first vaccination, suggesting immunological preconditioning similar to that described in heparin-induced thrombocytopenia. 12 Of note, no specific events were observed after the first dose of this vaccine, suggesting that the development of VITT after the second dose of ChAdOx1 nCoV-19 cannot be predicted on clinical grounds. Although the numbers are small, the clinical severity appears comparable to CVT-VITT after a first ChAdOx1 nCoV-19 dose, as 2 patients had an intracerebral hemorrhage, 1 had a concurrent venous thrombosis, and 2 patients died during admission. 4, 5, 13 Based on reported CVT cases to the registry, VITT appears to be much less common after a second ChAdOx1 nCoV-19 dose than after a first. However, since many countries, especially in Europe, restricted the use of the ChAdOx1 nCoV-19 vaccine after the emergence of VITT, the lower frequency of reported VITT after a second dose could partly be explained by the fact that fewer people received a second dose of ChAdOx1 nCoV-19 than a first dose. Even so, data from the European Centre for Disease Prevention and Control show that, until week 33 of 2021, 39 million first doses and 29 million second doses were administered in the European Economic Area. 14 Therefore, this imbalance cannot fully explain the difference in the incidence of VITT. Still, due to the risk of reporting bias, data from our registry must be interpreted cautiously when concluding that VITT is much less common after a second than after a first dose.

In conclusion, CVT-VITT can occur after the second dose of the ChAdOx1 nCoV-19 vaccine but was reported less often than after a first vaccine dose. Symptom onset of VITT may be more rapid after a second than after a first dose, but the low number of cases precludes firm conclusions. *According to the United Kingdom expert hematology panel. 9 †To avoid the possibility of patient identification, exact age has been removed. ‡In all cases, the first vaccination was ChAdOx1 nCoV-19. §Blood was drawn from the patient at admission, stored at 4 C for 1 wk, then stored at 220 C for 327 d before it was tested.

jjModified HIPA assay was performed as previously described. 15 ¶HIMEA assay was performed as previously described. For original data, please contact j.coutinho@amsterdamumc.nl.

The online version of this article contains a data supplement.

There is a Blood Commentary on this article in this issue.

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group. Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

Clinical features of vaccine-induced immune thrombocytopenia and thrombosis

Agestratified risk of cerebral venous sinus thrombosis after SARS-CoV-2 Vaccination

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis

Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?

Guidance from the Expert Haematology Panel (EHP) on Covid-19 vaccine-induced immune thrombocytopenia and thrombosis. VITT; 2021

Officially reported COVID-19 vaccination data -dashboard

International Cerebral Venous Thrombosis Consortium. COVID-19 vaccination and CVT study

Temporal aspects of heparin-induced thrombocytopenia

CVT After Immunisation Against COVID-19 (CAIAC) collaborators. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

European Centre for Disease Prevention and Control COVID-19 Vaccine Tracker

Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH